Document:

<PAGE>
                                                                    EXHIBIT 10.1

                          MERGER TERMINATION AGREEMENT

      This Merger Termination Agreement (this "Agreement") is entered into as of
December 13, 2005 by and among Medicis Pharmaceutical Corporation, a Delaware
corporation ("Parent"), Masterpiece Acquisition Corp., a Delaware corporation
and a wholly owned subsidiary of Parent ("Merger Sub"), and Inamed Corporation,
a Delaware corporation (the "Company").

                                    RECITALS

      WHEREAS, Parent, Merger Sub and the Company have entered into an Agreement
and Plan of Merger dated as of March 20, 2005 (the "Merger Agreement")
(capitalized terms used but not otherwise defined herein shall have the
respective meanings provided for such terms in the Merger Agreement); and

      WHEREAS, Parent, Merger Sub and the Company desire to terminate the Merger
Agreement as provided herein effective immediately upon execution of this
Agreement and Medicis' receipt of the Company Termination Fee and Reimbursement
Fees pursuant to Section 1(b) hereof.

                                    AGREEMENT

      NOW, THEREFORE, in consideration of the premises and the agreements set
forth herein, and intending to be legally bound hereby, the parties agree as
follows:

      1.    Termination of Merger Agreement.

            (a) Parent, Merger Sub and the Company hereby terminate the Merger
Agreement pursuant to Section 7.01 of the Merger Agreement, effective
immediately upon the execution of this Agreement and Medicis' receipt of the
Company Termination Fee and Reimbursement Fees pursuant to Section 1(b) hereof.

            (b) The Company shall pay to Parent (i) the Company Termination Fee
of $90,000,000 and (ii) $481,985 pursuant to Section 5.10(a) of the Merger
Agreement (the "Reimbursement Fees"), concurrently with the execution of this
Agreement. Payment of the Company Termination Fee and the Reimbursement Fees by
the Company shall be made by wire transfer of immediately available funds to the
account designated on Schedule 1 hereto. Parent and Merger Sub agree and
acknowledge that payment of the Termination Fee and the Reimbursement Fees shall
constitute full and final satisfaction of any and all obligations of the Company
under Section 5.10 of the Merger Agreement.

      2.    Effect of Termination; Mutual Discharge and Release.

            Each party hereto, on behalf of itself and, to the extent permitted
by law, its affiliates, subsidiaries, directors, officers, stockholders,
employees, agents, financial and legal advisors and other Representatives, and
the successors and assigns of each of them (each, a "Releasing Party"), hereby
fully, finally and forever releases each other party hereto and each of their
respective affiliates, subsidiaries, directors, officers, stockholders,
employees, agents, financial
<PAGE>
and legal advisors and other representatives, and the successors and assigns of
each of them, from any and all liabilities and obligations, claims, causes of
action and suits, at law or in equity, whether now known or unknown, based on or
arising out of facts of which such party has Knowledge (as defined below) on or
prior to the date hereof, whether arising under any United States federal, state
or local or any foreign law or otherwise, that any Releasing Party has or has
had arising out of, relating to, or in connection with the Merger Agreement and
the transactions contemplated thereby, including, without limitation, any
liability or obligation arising out of any breach based on facts of which such
party has Knowledge on or before the date hereof of any representation,
warranty, covenant or agreement contained in the Merger Agreement, provided that
nothing in this Section 2 shall impair the survival and full force of the terms
of the Confidentiality Agreement or Parent's right to receive immediate payment
of the Company Termination Fee and the Reimbursement Fees pursuant to Section 1
hereof and Section 5.10 of the Merger Agreement.

      3.    Survival of Confidentiality Agreement.

            (a) Notwithstanding anything contained in this Agreement to the
contrary, the provisions of the Confidentiality Agreement dated as of November
17, 2004 between Parent and the Company (the "Confidentiality Agreement") shall
survive and remain in full force and effect in accordance with their terms.

            (b) Each of Parent and Merger Sub, on the one hand, and the Company,
on the other hand, shall promptly deliver to the other all Proprietary
Information of the other party, and, at the other party's sole election, return
or destroy (provided that any such destruction shall be certified by a duly
authorized Representative of the party) all copies, reproductions, summaries,
analyses or extracts thereof or based thereon (whether in hard-copy form or on
intangible media, such as electronic mail or computer files) in the party's
possession or in the possession of any of its Representatives; provided, that if
a legal proceeding has been instituted to seek disclosure of the Proprietary
Information, such material shall not be destroyed until the proceeding is
settled or a final judgment with respect thereto has been rendered; and
provided, further, that all documents reflecting the party's final evaluation of
the Merger Agreement and the reasons for its decision to proceed or not to
proceed with the transactions contemplated thereby will not be required to be
returned or destroyed, however, the Confidentiality Agreement will continue to
apply to any such information on the terms set forth herein. Notwithstanding the
return or destruction of any Proprietary Information, or documents or material
containing or reflecting any Proprietary Information, the parties will continue
to be bound by their obligations of confidentiality and other obligations
hereunder for the term of the Confidentiality Agreement (or such other term as
may be applicable to the specific obligation).

      4. Representations and Warranties of Parent and Merger Sub. Parent and
Merger Sub hereby represent to the Company as follows: Each of Parent and Merger
Sub has full corporate power and authority to execute, deliver and perform this
Agreement; this Agreement has been duly and validly authorized by their
respective boards of directors and executed and delivered by each of them, and
constitutes a valid binding obligation of each of them, enforceable against each
of them in accordance with its terms, except as such enforceability may be
limited by bankruptcy, insolvency, fraudulent conveyance reorganization,
moratorium or other similar laws now or hereafter in effect relating to
creditors' rights generally and by general equitable principles; and neither
Parent nor Merger Sub have assigned, transferred or conveyed to any other Person
any claim

                                       2
<PAGE>
or any portion thereof or interest therein relating to any of the matters that
are the subject of this Agreement.

      5. Representations and Warranties of the Company. The Company hereby
represents to Parent as follows: The Company has full corporate power and
authority to execute, deliver and perform this Agreement; this Agreement has
been duly and validly authorized by the Company's board of directors and
executed and delivered by the Company, and constitutes a valid binding
obligation of the Company, enforceable against the Company in accordance with
its terms, except as such enforceability may be limited by bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other similar
laws now or hereafter in effect relating to creditors' rights generally and by
general equitable principles; the Company has available and ready funds
sufficient to pay the amounts set forth in Section 1 hereof; and the Company has
not assigned, transferred or conveyed to any other Person any claim or any
portion thereof or interest therein relating to any of the matters that are the
subject of this Agreement.

      6. Public Announcement. Parent and the Company acknowledge that each
intends to issue a press release promptly after the date of this Agreement with
respect to this Agreement and the termination of the Merger Agreement. Each of
Parent and the Company shall use reasonable efforts to consult with the other
before issuing such press release, and in no event may either party issue such
press until the termination of the Merger Agreement has become effective
pursuant to Section 1 hereof.

      7.    Governing Law; Waiver of Jury Trial.

            (a) This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to the conflict of
law provisions thereof. This Agreement shall be binding upon any successor to
the Company or Parent or Merger Sub. In addition, each of the parties hereto (a)
irrevocably and unconditionally consents to submit itself to the jurisdiction of
the Court of Chancery of the State of Delaware in the event any dispute arises
out of this Agreement or the transactions contemplated by this Agreement, (b)
agrees that it will not attempt to deny or defeat such personal jurisdiction by
motion or other request for leave from any such court, (c) agrees that it will
not bring any action relating to this Agreement or the transactions contemplated
by this Agreement in any court other than the Court of Chancery of the State of
Delaware, and each of the parties irrevocably waives the right to trial by jury,
(d) waives, to the fullest extent permitted by law, the defense of an
inconvenient forum to the maintenance of such action on the Court of Chancery of
the State of Delaware, and (e) irrevocably consents to service of process by
first class certified mail, return receipt requested, postage prepaid, to the
address at which such party is to receive notice.

            (b) Each of the parties hereto hereby waives to the fullest extent
permitted by applicable law any right it may have to a trial by jury with
respect to any litigation directly or indirectly arising out of, under or in
connection with this Agreement or the Merger Agreement.

      8. Specific Performance. The parties hereto agree that irreparable damage
would occur in the event any provision of this Agreement were not performed in
accordance with the terms hereof and that the parties shall be entitled to
specific performance of the terms hereof, in addition to any other remedy at law
or in equity. It is accordingly agreed that in any proceeding seeking specific
performance each of the parties will waive the defense of adequacy of a remedy
at law.

                                       3
<PAGE>
      9.    Miscellaneous.

            (a) The descriptive headings contained in this Agreement are
included for convenience of reference only and shall not affect in any way the
meaning or interpretation of this Agreement.

            (b) Each party agrees to use reasonable effort to take reasonable
actions as any other party may reasonably request to carry out the intent of
this Agreement and to take any other actions required under applicable Law to
carry out and effectuate the intent of this Agreement.

            (c) This Agreement, the Merger Agreement and the Confidentiality
Agreement constitute the entire agreement among the parties hereto with respect
to the subject matter hereof and supersede all prior agreements, understandings
and negotiations, both written and oral, between the parties with respect to the
subject matter of this Agreement. No representation, inducement, promise,
understanding, condition or warranty not set forth herein has been made or
relied upon by either party hereto in connection with this Agreement.

            (d) This Agreement may be modified or amended only by a writing
signed by the parties hereto. This Agreement may be executed and delivered
(including by facsimile transmission) in one of more counterparts, and by the
different parties hereto in separate counterparts, each of which when executed
and delivered shall be deemed to be an original but all of which taken together
shall constitute one and the same agreement.

            (e) If any provision of this Agreement is held to be illegal,
invalid or unenforceable under any present or future laws, and if the rights or
obligations of any party hereto under this Agreement will not be materially and
adversely affected thereby, (a) such provision will be fully severable, (b) this
Agreement will be construed and enforced as if such illegal, invalid or
unenforceable provisions had never comprised a part hereof, and (c) the
remaining provisions of this Agreement will remain in full force and effect and
will not be affected by the illegal, invalid or unenforceable provision or by
its severance herefrom.

            (f) If any legal action, including, without limitation, an action
for arbitration or injunctive relief, is brought relating to this Agreement or
the Merger Agreement or the breach or alleged breach hereof or thereof, the
prevailing party in any final judgment or arbitration award, or the
non-dismissing party in the event of a voluntary dismissal by the party
instituting the action, shall be entitled to the full amount of all reasonable
legal expenses, including all court costs, arbitration fees and actual
attorneys' fees paid or incurred in good faith.

            (g) A party hereto shall be deemed to have "Knowledge" of a
particular fact or other matter, and a particular fact or other matter shall be
deemed "known to" a party hereto if any executive officer of such party (a) is
actually aware of such fact or matter, or (b) would be expected to discover or
otherwise become aware of such fact or other matter after consultation with its
outside legal advisors.

                                       4
<PAGE>
      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their respective authorized officers as of the day and year
first above written.

                        MEDICIS PHARMACEUTICAL CORPORATION

                         By: /s/ Mark A. Prygocki, Sr.
                             ---------------------------------------------------
                             Name:   Mark A. Prygocki, Sr.
                             Title:  Executive Vice President, Chief Financial
                                     Officers, Corporate Secretary and Treasurer

                         MASTERPIECE ACQUISITION CORP.

                         By: /s/ Mark A. Prygocki, Sr.
                             ---------------------------------------------------
                             Name:   Mark A. Prygocki, Sr.
                             Title:  Vice President, Secretary and Chief
                                     Financial Officer

                         INAMED CORPORATION

                         By: /s/ Nicholas Teti
                             ---------------------------------------------------
                             Name:  Nicholas Teti
                             Title: Chairman, President and Chief Executive
                                    Officer

                                       5Exhibit 10.1

    Exhibit
      10.1

    

    CIGNA
      Corporation Non-Employee Director Compensation Program

    Effective
      January 1, 2006

    

    Board
      and Committee Retainers

    

    Board
      retainer.
      Each
      Director receives $225,000 annually for Board membership. One third ($75,000)
      of
      the retainer is payable in cash and two-thirds ($150,000) of the retainer is
      payable in deferred stock units. Each
      deferred stock unit represents the value of one share of CIGNA Corporation
      common stock and constitutes the right to a future cash payment equal to (a)
      the
      fair market value of one share at payout and (b) the accumulated amount of
      dividends paid on each share of CIGNA common stock from the date of award of
      the
      deferred stock units until the date of payment (hypothetical
      dividends). 

     

    Committee
      member retainer.
      Each
      Director receives $10,000 annually for each committee membership. Committee
      chairs and members of the Executive Committee do not receive this retainer.
      

     

    Committee
      chair retainer.
      Each
      committee chair other than the chair of the Executive Committee receives $15,000
      annually. 

    

    Payment
      of Retainers. 

    	§  	
            The
              committee member and committee chair retainers as well as the cash
              portion
              of the Board retainer are paid in cash quarterly.
              

          

    	§  	
            Deferred
              stock units are awarded quarterly. Their cash value is paid on the
              third
              anniversary of the award, or upon separation from service, if
              earlier. 
              Hypothetical dividends are treated as reinvested and are paid out with
              the
              stock unit payment.

          

     

    Deferred
      compensation elections.
      Directors may elect to defer some or all of their compensation under the
      Deferred Compensation Plan for Directors of CIGNA Corporation. 

     

    Other
      Director Benefits

     

    Basic
      Life Insurance coverage. Each
      Director is provided coverage in the amount of the annual board
      retainer.

    

    Travel
      accident coverage.
      Each
      Director is provided coverage in the amount of three times the annual board
      retainer. 

     

    Financial
      planning.
      Directors may use the financial planning services available to CIGNA executives.
      

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    Insurance.
      Directors may purchase or participate, on an after-tax basis, in life insurance,
      medical/dental care programs, long-term care, property/casualty personal lines
      and various other insurance programs available to CIGNA employees. 

    

    Matching
      Gifts. Directors
      may participate in the matching charitable gift program available to CIGNA
      employees, under which up to $5,000 annually may be matched. 

    

    Post-Termination
      Benefits. Directors
      serving on January 1, 2006 are eligible, upon termination after nine years
      of
      Board service, to continue to participate, in medical/dental care programs
      on an
      after-tax basis for two years and financial planning services (of up to $5,000)
      for one year following separation of service from the Board. These directors
      are
      also provided $10,000 basic life insurance coverage for life. Previously,
      Directors who retired generally were eligible to use financial planning services
      for five years, to participate for life in medical/dental care programs on
      an
      after-tax basis and were provided $10,000 basic life insurance coverage for
      life. All directors may, at their own expense and if otherwise eligible, also
      continue life insurance, long-term care insurance and property/casualty personal
      lines insurance pursuant to the terms of the applicable policies. 

    

    Share
      Ownership Guidelines 

    

    Each
      Director is required to hold CIGNA common stock or CIGNA common stock units
      with
      a value equal to or greater than $250,000. Each Director has three
      years from
      the
      time he or she joins the Board to accumulate the required shares.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]